Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

What will it take for a clinical-stage biotech to break into the cardio space? One CEO thinks he has the answer.

South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.

Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...

Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Scholar Rock submitted its BLA of apitegromab for the treatment of patients with Spinal Muscular Atrophy with a request for ...

US pharma major Eli Lilly today announced its financial results for the fourth quarter of 2024 and detailed 2025 financial ...

Much like liraglutide, tirzepatide is also currently only ... As it stands right now, Lexaria is likely the only biotechnology company in existence that has demonstrated success utilizing all ...

Much like liraglutide, tirzepatide is also currently only available in an ... As it stands right now, Lexaria is likely the only biotechnology company in existence that has demonstrated success ...

Much like liraglutide, tirzepatide is also currently only available in an ... As it stands right now, Lexaria is likely the only biotechnology company in existence that has demonstrated success ...